Special remarks:

INTRODUCTION 

Incretins  are  a  group  of  gastrointestinal  hormones  that  cause  an  increase  in  the amount  of  insulin  released  from  the  beta  cells  of  the  islets  of  Langerhans  after eating.  They  also  inhibit  glucagon  release  from  the  alpha  cells  of  the  islets  of Langerhans. As a result, they slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake.   

The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1    (GLP-1)    and    Gastric    inhibitory    peptide    (or    glucose-dependent insulinotropic polypeptide or GIP).   

The  human  proglucagon  gene  was  cloned  in  1983,  and  the  human  proglucagon sequence  was  subsequently  deduced.  After  that,  it  was  found  that  the  specific sequence  of  GLP-1  has  insulinotropic  effect:  GLP-1  (7-36)  amide.  Now,  GLP-1 (7-36)  amide  and  GLP-1  (7-37)  are  known  as  active  forms  of  GLP-1.  They  are rapidly inactivated to GLP-1 (9-36) amide and GLP-1 (9-37) by DPP-IV within a few moments in blood. Currently, Several DPP-IV inhibitors that can be taken orally as a tablet have already been developed as a treatment for diabetes.

This ELISA kit can measure Active forms of GLP-1 (GLP-1 (7-36) amide and GLP-1
(7-37)) specifically.
 
PRINCIPLE

This kit is a solid phase sandwich ELISA using 2 kinds of highly specific antibodies. Tetra  Methyl  Benzidine  (TMB)  is  used  as  a  coloring  agent  (Chromogen).  The strength of coloring is proportional to the quantities of active form of GLP-1.